Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

ABCG2 Protein Levels and Association to Response to First-Line Irinotecan-Based Therapy for Patients with Metastatic Colorectal Cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. New Aspects of the Kidney in the Regulation of Fibroblast Growth Factor 23 (FGF23) and Mineral Homeostasis

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Age-Associated Salivary MicroRNA Biomarkers for Oculopharyngeal Muscular Dystrophy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Genetic Biomarkers in Melanoma of the Ocular Region: What the Medical Oncologist Should Know

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Exercise Oncology and Immuno-Oncology; A (Future) Dynamic Duo

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Prognostic utility of serum YKL-40 in patients with cervical cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Triage May Improve Selection to Colonoscopy and Reduce the Number of Unnecessary Colonoscopies

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

In this study we investigated the use of cancer cell protein expression of ABCG2 to predict efficacy of systemic first-line irinotecan containing therapy in patients with metastatic colorectal cancer (mCRC). From a Danish national cohort, we identified 119 mCRC patients treated with irinotecan containing therapy in first-line setting. Among these, 108 were eligible for analyses. Immunohistochemistry (IHC) analyses were performed on the primary tumor tissue in order to classify samples as high or low presence of ABCG2 protein. Data were then associated with patient outcome (objective response (OR), progression free survival (PFS) and overall survival (OS)). ABCG2 protein expression in the basolateral membrane was high (score 3+) in 33% of the patients. Exploratory analyses revealed a significant interaction between ABCG2 score, adjuvant treatment and OR (p = 0.041) in the 101 patients with evaluable disease. Patients with low ABCG2 (score 0-2) and no prior adjuvant therapy had a significantly higher odds ratio of 5.6 (Confidence Interval (CI) 1.68-18.7; p = 0.005) for obtaining OR. In contrast, no significant associations between ABCG2 expression and PFS or OS were found. These results suggest that measurement of the ABCG2 drug efflux pump might be used to select patients with mCRC for irinotecan treatment. However, additional studies are warranted before conclusions regarding a clinical use can be made. Moreover, patients with high ABCG2 immunoreactivity could be candidates for specific ABCG2 inhibition treatment in combination with irinotecan.

OriginalsprogEngelsk
Artikelnummer5027
TidsskriftInternational Journal of Molecular Sciences
Vol/bind21
Udgave nummer14
Sider (fra-til)1-13
Antal sider13
ISSN1661-6596
DOI
StatusUdgivet - 16 jul. 2020

ID: 60682236